https://www.selleckchem.com/pr....oducts/CI-1040-(PD18
However, there was no statistical difference in survival when comparing the various RAS mutations, including the comparison of G12C to G12S (p=0.38). Patients with cancer harbouring rare RAS mutations had a median survival of 30 months. Whilst the G12S mutation was associated with the longest survival numerically, the observed survival for patients with the most common RAS mutations (G12C, G12V, G12A, G12D and G13D) did not significantly differ. Whilst the G12S mutation was associated with the longest survival numerically, th
Like
Comment
Share
